AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00962728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory Threshold Device (Res-Q-Gard ITD)
Description: Patient will breathe through this device attached to a mouthpiece during assessment of orthostatic tolerance.
Study NCT00962728 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Inspiratory Threshold Device
Description: Breathing through a respiratory particulate filter (Model 002850P, Sims Portex Inc, Keene NH) which will have minimal resistance.
Study NCT04062266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV
Study NCT00680602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI (fluoxetine, sertraline, paroxetine, citalopram)
Description: Fluoxetine (80mg/day or maximum tolerated dosage) Sertraline (200mg/day or maximum tolerated dosage) Paroxetine (60 mg/day or maximum tolerated dosage) Citalopram (60 mg/day or maximum tolerated dosage)
Study NCT01357070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Brocco-sprout homogenate
Description: Participants will be asked to orally consume on three consecutive days a brocco-sprout homogenate (70g dry weight).
Study NCT01357070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Alfalfa sprout homogenate
Description: Participants will be asked to orally consume on three consecutive days an alfalfa sprout homogenate.
Study NCT01910584 — intervention group
Intervention type: PROCEDURE
Intervention: Novasure endometrial ablation
Description: Novasure endometrial ablation is the second generation endometrial ablation treatment aimed to cure the dysfunctional uterine bleeding(DUB),including menorrhagia.
Study NCT01034436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: fatty acid quality and overweight
Description: Duration 12 weeks
Study NCT01034436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fatty acid quality and overweight
Description: Duration 12 weeks
Study NCT03916549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The acupuncture procedure is performed by one well trained person, 1 time per week in total of 10 weeks on the same day time. Sterile, disposable, stainless steel acupuncture needles (40x0.25 mm diameter) were inserted to corporal acupoints, with initial gentle stimulation by quick rotation of 1080°, after then leaving needle in located place for twenty minutes. Needling deep - 0.5-1 cm. If the intent was to invigorate - the needle was inserted to the flow of energy; if harmonization needed - the needle was placed perpendicular to the point flow of energy; if sedation was needed, needles were placed against to the flow of energy on channel. The selection of acupoints was based according by traditional Chinese medicine, literature findings.
Study NCT04062266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT00248365 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Theralux extracorporeal photochemotherapy
Study NCT01987284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02863679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tetracaine hydrochloride gel
Description: Tetracaine hydrochloride gel contains 1% tetracaine hydrochloride, and a fair dose of fungicide, lubricants, remove foam agent, as the long-term local anesthetics.
Study NCT02863679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine hydrochloride gel
Description: Tetracaine hydrochloride gel contains 1% tetracaine hydrochloride, and a fair dose of fungicide, lubricants, remove foam agent, as the long-term local anesthetics.
Study NCT00838877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: radioligand [18F]AZD4694
Description: single dose of iv. admin. 1-2 times per subject
Study NCT00838877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: radioligand [11C]AZD2184
Description: single dose of iv admin. 1 time per subject
Study NCT01992107 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIVc
Description: Novartis Investigational Quadrivalent Vaccine
Study NCT01992107 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV1c
Description: Licensed Influenza Vaccine
Study NCT01992107 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV2c
Description: Novartis Investigational Vaccine
Study NCT01604213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin plus vildagliptin
Description: Oral Metformin 850mg and vildagliptin 50mg, qd initially, up-titrated to BID if clinically necessary
Study NCT01604213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin only
Description: Oral Metformin 850mg QD, up-titrated to 850mg TID is clinically indicated
Study NCT00804609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DepoDur following epidural lidocaine
Description: All participant underwent cesarean delivery. An epidural top-up anesthetic consisting of 2% lidocaine with epinephrine 1:200,000 and sodium bicarbonate (1 meq per 10 mL lidocaine) was given. The lidocaine solution was administered in 5 mL increments every 2.5 minutes until a T6 sensory level to touch was attained. Patients also received a 100 mcg dose of fentanyl epidurally after the lidocaine solution had been administered.~Provided delivery had occurred at least 60 minutes after the initial lidocaine administration, patients received EREM 8 mg (DepoDur™) administered through the epidural catheter. A 2 mL epidural saline flush was administered before and after drug administration.
Study NCT00804609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DepoDur following spinal anesthetic
Description: Participants underwent an elective cesarean delivery with a combined spinal/epidural. All patients received 12 mg hyperbaric bupivacaine with 20 mcg fentanyl administered intrathecally. No local anesthetic was administered through the catheter. The combined spinal-epidural was performed at the L2/L3 or L3/L4 interspace and the intrathecal dose was injected over 5-10 s. A multiple orifice epidural catheter was threaded 5 cm into the epidural space.~Provided delivery had occurred 60 minutes after the intrathecal dose patients received EREM 8 mg (DepoDur™) through the epidural catheter. A 2 mL epidural saline flush was administered before and after drug.
Study NCT00817362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-504
Description: IPI-504 IV infusion 300 mg/m2
Study NCT00817362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab IV infusion 8 mg/kg as the first dose of trastuzumab, followed by trastuzumab 6 mg/kg every 3 weeks. Subjects whose last dose of trastuzumab was \<4 weeks prior to study entry will receive 6 mg/kg as the first dose of trastuzumab. For all additional cycles in Stage 1, trastuzumab will be administered with the first dose of IPI-504.
Study NCT02434133 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw/Data Collection
Description: Participation will involve an extra 8ml tube of blood and a review of their medical records for medications and immunization history.
Study NCT02308540 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIILPCV10
Description: 10-valent Pneumococcal Conjugate Vaccine (SIILPCV10) at a dosage of 2 µg for each serotype polysaccharide, except 4 µg for 6B serotype, conjugated to a carrier protein (CRM197), with adjuvant (aluminum phosphate \[alum\]) and preservative (thiomersal).
Study NCT03333850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual feedback of physical activity
Description: A monitor (tablet) will display the level of physical activity during hospitalisation. The monitor will be placed at the bedside (table).
Study NCT03333850 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No feedback of physical activity
Description: There will be no visual feedback of the physical activity (no monitor placed at the bedside (table)).
Study NCT03333850 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of physical activity
Description: A pair of accelerometers placed on the chest and on the thigh will measure the physical activity level during hospitalisation. The measurement is made continuously and stored on a secure web-server.
Study NCT03333850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of physical activity
Description: A pair of accelerometers placed on the chest and on the thigh will measure the physical activity level during hospitalisation. The measurement is made continuously and stored on a secure web-server.
Study NCT02229006 — intervention group
Intervention type: RADIATION
Intervention: 18F-NaF PET-CT
Study NCT02308540 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax 23
Description: 23-valent Pneumococcal Polysaccharide Vaccine (Pneumovax 23; MSD Pharmaceuticals) for the adult cohort.
Study NCT02308540 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13
Description: 13-valent Pneumococcal Conjugate Vaccine (Prevenar 13; Pfizer-Wyeth) for the toddler and infant cohorts
Study NCT03439761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT-112 Injection
Description: PT-112 Injection 28 days constitute a period. The drug is intravenously dripped for 60 minutes at the 1st, 8th and 15th day of each period.
Study NCT01222520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan and amlodipine
Description: Telmisartan 80 mg and amlodipine 5 mg once a daily
Study NCT01222520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: 80 mg once a daily
Study NCT05499754 — intervention group
Intervention type: OTHER
Intervention: pLMA: PROSEAL LARYNGEAL MASK, sLMA : SUPREMA LARYNGEAL MASK, I-jel =I-GEL
Description: a SAD was inserted by all anaesthetists participating in the study had at least 3 years experience of airway management and were experienced with both the pLMA, sLMA and I-jel. Inadequate ventilation after two attempts was considered a failed placement, and these patients were excluded, while the practitioner was freed to use an alternative airway device.
Study NCT00685204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milataxel
Description: Milataxel is a liquid that is dosed orally at 60 mg/m2 on Day 1 of a 21 day cycle. If no toxicities of greater than Grade 1 severity occur, patients will receive 75 mg/m2 for the second and subsequent cycles.
Study NCT00546065 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: esomeprazole treatment
Description: concomitant esomeprazole treatment
Study NCT00546065 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: esomeprazole treatment
Description: concomitant esomeprazole treatment
Study NCT00966524 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: Pregraduates medical students will be randomized to perform endotracheal intubation with video-guided feedback (experimental arm) or endotracheal intubation using direct visualization feedback (standard technique).
Study NCT00966524 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Description: Pregraduates medical students will be randomized to perform endotracheal intubation with video-guided feedback (experimental arm) or endotracheal intubation using direct visualization feedback (standard technique).
Study NCT04824326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PSAI-CA
Description: The intervention is based on the principles of the teaching of the ancient Greek philosopher Pythagoras. These principals set a basic framework for behavior on the basis of experiential learning and weekly evaluation of the implementation of 12 virtues. The technique is practiced twice a day(before night sleep and in the morning before getting up from bed) and evolves into five successive steps;1)reading of the 12 virtues and diaphragmatic breathing, 2)recall every event og the day,3)third person visualization and self-observation, 4)self-dialogue What have I done wrong?, What have I done right?, What have I omitted that I ought to have done? Endorsement or disapproval of actions according to the 12 virtues and the instructions for a healthy lifestyle, 5) next morning brief revision of the previous night's conclusions and setting of goals for the upcoming day.
Study NCT00217373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine
Description: Given SC
Study NCT00217373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa-2b
Description: Given SC
Study NCT00217373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine
Description: Given SC
Study NCT00217373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study NCT00537576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose LACTIN-V applicator
Description: Low dose LACTIN-V applicator (150 mg LACTIN-V, 5.0 x 10\^8 CFU), administered vaginally once a day for 5 consecutive days
Study NCT00537576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium dose LACTIN-V applicator
Description: Medium dose LACTIN-V applicator (300 mg LACTIN-V, 1.0 x 10\^9 CFU), administered vaginally once a day for 5 consecutive days
Study NCT00537576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose LACTIN-V applicator
Description: High dose LACTIN-V applicator (600 mg LACTIN-V, 2.0 x 10\^9 CFU), administered vaginally once a day for 5 consecutive days
Study NCT00537576 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low dose Placebo applicator
Description: Low dose Placebo applicator (150 mg Placebo), administered vaginally once a day for 5 consecutive days
Study NCT00537576 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Medium dose Placebo
Description: Medium dose Placebo applicator (300 mg Placebo), administered vaginally once a day for 5 consecutive days
Study NCT00537576 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High dose Placebo applicator
Description: High dose Placebo applicator (600 mg Placebo), administered vaginally once a day for 5 consecutive days
Study NCT00975611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amantadine Hydrochloride, USP
Description: amantadine tablets 100 mg. BID for 4 weeks
Study NCT00975611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amantadine Hydrochloride, USP
Description: amantadine 200 mg. tablets BID for 4 weeks
Study NCT00975611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets BID, for 4 weeks
Study NCT04233112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Description: Capsules containing 5mg melatonin will be prepared by Delta Care RX™ Pharmacy. Participants will be asked to take them nightly for one year.
Study NCT04233112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osteogenic loading
Description: Osteogenic loading device therapy includes the emulation of impact forces through kinetic chains of natural impact absorption with fixtures that have the ability to capture bone compression data. Participants will be asked to perform osteogenic loading once per week.
Study NCT04179071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Subject will receive savolitinib tablet 600mg orally after a high-fat, high-calorie meal.
Study NCT04179071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Subjects will receive famotidine tablet 40mg orally after an overnight (minimum 8hours) of fasting.
Study NCT04203680 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: HTK cardioplegic solution
Description: 30 ml/kg of HTK cardioplegic solution at 4°C through an antegrade fashion at an initial perfusion pressure of 80-100 mmHg
Study NCT04203680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: blood cardioplegia
Description: one liter of blood cardioplegia was given with the antegrade route at 30°C, or lower. Blood maintenance cardioplegia was repeated every 30-45mins
Study NCT04233112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mock for Osteogenic Loading
Description: Mock osteogenic loading will occur using the osteogenic loading device therapy includes the emulation of impact forces through kinetic chains of natural impact absorption with fixtures that have the ability to capture bone compression data. Participants will be asked to perform mock osteogenic loading once per week.
Study NCT04233112 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mock for Osteogenic Loading
Description: Mock osteogenic loading will occur using the osteogenic loading device therapy includes the emulation of impact forces through kinetic chains of natural impact absorption with fixtures that have the ability to capture bone compression data. Participants will be asked to perform mock osteogenic loading once per week.
Study NCT04233112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (plant fiber) for melatonin
Description: Capsules containing plant fiber will be prepared by Delta Care RX™ Pharmacy. Participants will be asked to take them nightly for one year.
Study NCT04233112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (plant fiber) for melatonin
Description: Capsules containing plant fiber will be prepared by Delta Care RX™ Pharmacy. Participants will be asked to take them nightly for one year.
Study NCT06733857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VEG2
Description: Participants were provided with a caloric target to place them in a ∼0 to 10% energy surplus, and a protein target of 2 g·kg bm-1·d-1. Participants were instructed to avoid animal products for ≥6 d per wk, focusing their intake on protein-rich non-animal-derived foods (for example, mycoprotein-containing products, pulses, soy). To facilitate reaching protein intake targets, the research team provided participants with mycoprotein-containing vegan products (∼1-2 products per day) to be used as the main protein source for some meals. This group also received 105-g mycoprotein (46-g protein, 10-g carbohydrate, 13-g fat, 348 kcal), 35-g post-training, and 70-g before bed.
Study NCT00573274 — intervention group
Intervention type: DEVICE
Intervention: Physioflow Impedance
Description: 6 ECG leads applied to the neck and thorax for the duration of surgery (approximately 1 hour).
Study NCT01895374 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser treatments
Study NCT01895374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser treatments
Study NCT06733857 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OMNI2
Description: Participants were provided with a caloric target to place them in a ∼0 to 10% energy surplus, and a protein target of 2 g·kg bm-1·d-1. Participants in OMNI2 were instructed to consume an omnivorous diet, focusing their intake on high-quality animal-derived proteins (that is, meat, milk, yogurt, cheese). To facilitate reaching protein intake targets, the research team provided participants with a weekly supply (∼1-2 products per day) of chicken or beef to be used as the main protein source for some meals. This group also received 59-g supplemental milk protein daily (47-g protein, 2-g carbohydrate, \<1-g fat, 198 kcal) 19.5-g to drink post-training and 39-g to drink before sleep.
Study NCT01895374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: amniotic membrane application
Study NCT01895374 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hydrocolloid application
Study NCT03324347 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapydog
Description: Presence of a therapydog during a clinical examination in a dental clinic
Study NCT01045577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Masitinib
Description: 6 mg/kg/day
Study NCT01045577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Masitinib
Description: 3 mg/kg/day
Study NCT01045577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching masitinib (3 mg/kg/day and 6 mg/kg/day)
Study NCT02056015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]MLN6907
Description: IV Administration of \[68Ga\]MLN6907 on Day 1
Study NCT03775902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo tablet
Study NCT03775902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil
Description: 20 mg nicorandil (Ikorel, Sanofi Winthrop Industrie; NIC)
Study NCT01901068 — intervention group
Intervention type: DEVICE
Intervention: MonoMax
Description: Abdominal wall will be closed with MonoMax after an elective primary laparotomy.
Study NCT03763422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Oral Administration of Temozolomide
Study NCT03763422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral Administration of Temozolomide
Study NCT03763422 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 50.4 Gy in 28 fractions over 6 weeks
Study NCT03763422 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 50.4 Gy in 28 fractions over 6 weeks
Study NCT03763422 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery